PETS
PETMED EXPRESS INC
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$1.15
−2.54%Year over year
Reported trailing growth
- Revenue
- -19.7%
- EBITDA
- +29.9%
- EBIT
- —
- EPS
- +35.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +9.2%
- EBITDA
- +94.5%
- EPS
- +68.8%
Three-year CAGR
- Revenue
- -11.3%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026